RAPP Stock Rapport Therapeutics, Inc.
US · NasdaqGMLast in our picks 2026-10-21 — not in the current list; analysis below is from that screen
Positive clinical results and rising targets provide asymmetric upside for this liquid specialty biotech.
Future value: $64.97 (+121.22%) · 6-12 months · analyst consensus
Signal breakdown
- ▸BTIG raised target to $89 while maintaining Buy after trial results.
- ▾Below 50-day MA (-27.26%)
- ▸Volume 17.33× average — accumulation
- ▸~121% upside to price target
Is RAPP a buy right now?
Trend: RAPP is trading below the 50-day average (-34.38%), RSI 61 — neutral momentum, with a 3-month return of -39.63%.
Valuation & quality: Rapport Therapeutics, Inc. trades on forward P/E -5.0, price-to-book 2.87; fundamentals show net margin 0.0%, return on equity -40.0%.
Analyst consensus: 14 analysts have a mean 12-month price target of $68.29 (+169.6% vs the last close; range $50.00 – $91.00), consensus rating “strong buy”.
Our screen: STRONG BUY (score 4) — Positive clinical results and rising targets provide asymmetric upside for this liquid specialty biotech.
Computed from end-of-day data; not personal advice.
Our track record with RAPP
First flagged in our daily picks as BUY on 2026-10-21 at $29.37 — -13.8% since.
Paper trades from our simulated funds at real end-of-day prices; past results don't predict future returns.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +7.80% | +5.90% | +19.20% | +5.50% | -1.70% | +18.80% | -31.00% | -24.60% |
Fundamentals
Analyst price target
Technical signals
About Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders.
Sector: Healthcare · Industry: Biotechnology · United States · 84 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.